Eam Investors, LLC Tg Therapeutics, Inc. Transaction History

Eam Investors, LLC

$581 Million
Q3 2024

A detailed history of Eam Investors, LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Eam Investors, LLC holds 175,959 shares of TGTX stock, worth $5.2 Million. This represents 0.71% of its overall portfolio holdings.

Number of Shares

175,959

Holding current value

$5.2 Million

% of portfolio

0.71%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$17.21 - $25.28 $3.03 Million - $4.45 Million	175,959 New	175,959 $4.12 Million
Q2 2023 Aug 11, 2023	SELL	$15.48 - $35.0 $858,876 - $1.94 Million	-55,483 Reduced 39.62%	84,552 $2.1 Million
Q1 2023 Jul 12, 2023	BUY	$10.23 - $19.34 $1.01 Million - $1.9 Million	98,426 Added 236.55%	140,035 $2.11 Million
Q1 2023 May 12, 2023	SELL	$10.23 - $19.34 $1.27 Million - $2.4 Million	-123,838 Reduced 74.85%	41,609 $625,000
Q4 2022 Feb 14, 2023	BUY	$5.01 - $11.83 $828,889 - $1.96 Million	165,447 New	165,447 $1.96 Million
Q2 2021 Aug 13, 2021	SELL	$32.5 - $48.96 $1.91 Million - $2.87 Million	-58,675 Closed	0 $0
Q1 2021 May 11, 2021	SELL	$41.61 - $54.3 $273,377 - $356,751	-6,570 Reduced 10.07%	58,675 $2.83 Million
Q4 2020 Feb 11, 2021	SELL	$25.27 - $54.9 $789,308 - $1.71 Million	-31,235 Reduced 32.37%	65,245 $3.39 Million
Q3 2020 Nov 13, 2020	SELL	$18.49 - $27.24 $1.1 Million - $1.62 Million	-59,604 Reduced 38.19%	96,480 $2.58 Million
Q2 2020 Aug 13, 2020	BUY	$8.9 - $21.84 $1.39 Million - $3.41 Million	156,084 New	156,084 $3.04 Million
Q4 2017 Feb 12, 2018	SELL	$7.35 - $12.3 $2.26 Million - $3.79 Million	-308,120 Closed	0 $0
Q3 2017 Nov 08, 2017	BUY	$10.0 - $12.7 $3.08 Million - $3.91 Million	308,120	308,120 $3.65 Million

Others Institutions Holding TGTX

# of Institutions

338

Shares Held

88.3M

Call Options Held

2.35M

Put Options Held

1.7M

View Full List

About TG THERAPEUTICS, INC.

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.29B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

More about TGTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eam Investors, LLC with notifications on news.

Account

Eam Investors, LLC Tg Therapeutics, Inc. Transaction History